NA808

NA808 is a locked nucleic acid (LNA)-modified antisense oligonucleotide developed by Chugai Pharmaceutical for the treatment of chronic hepatitis C virus (HCV) infection. It targets microRNA-122 (miR-122), a liver-specific microRNA that is essential for the stability and replication of the HCV RNA genome. By sequestering miR-122, NA808 prevents its interaction with the 5' untranslated region of the viral RNA, thereby inhibiting viral replication. The drug was evaluated in Phase I clinical trials as an intravenous therapy administered once weekly, representing a host-targeting approach to antiviral therapy that is distinct from traditional direct-acting antivirals (DAAs).